Background
Methods
Patients
TACE procedure and treatment schedule
Outcomes and assessments
Statistical analysis
Results
Baseline patient characteristics
Variables | SNUH (n = 421) | EUMC (n = 176) | SMC (n = 739) | P |
---|---|---|---|---|
Sex | ||||
Male | 333 (79.1) | 141 (80.1) | 583 (78.9) | 0.938 |
Female | 88 (20.9) | 35 (19.9) | 156 (21.1) | |
Age (year) | 63 (54–71) | 69 (59–78) | 63 (56–70) | < 0.001 |
Etiology | ||||
HBV | 265 (63.0) | 121 (74.6) | 517 (70.0) | 0.005 |
HCV | 56 (13.3) | 26 (16.0) | 97 (13.1) | |
alcohol | 45 (10.7) | 15 (9.4) | 67 (9.0) | |
Cirrhosis | ||||
Yes | 336 (79.8%) | 134 (76.1%) | 443 (60.0) | < 0.001 |
Child-Pugh classa | ||||
A | 336 (79.8) | 143 (81.3) | 638 (86.3) | 0.010 |
B | 85 (20.2) | 33 (18.8) | 101 (13.7) | |
BCLC stage | ||||
A | 168 (39.9) | 69 (39.2) | 500 (67.7) | < 0.001 |
B | 253 (60.1) | 107 (60.8) | 239 (32.3) | |
ALBI grade | ||||
1 | 159 (37.8) | 45 (25.6) | 339 (45.9) | < 0.001 |
2 | 245 (58.2) | 118 (67.0) | 385 (52.1) | |
3 | 17 (4.0) | 13 (7.4) | 15 (2.0) | |
HAP score | ||||
A | 157 (37.3) | 58 (33.0) | 233 (31.5) | 0.016 |
B | 134 (31.8) | 47 (26.7) | 252 (34.1) | |
C | 106 (25.2) | 48 (27.3) | 204 (27.6) | |
D | 24 (5.7) | 23 (13.1) | 50 (6.8) | |
Modified HAP score | ||||
A | 211 (50.1) | 71 (40.4) | 98 (13.3) | < 0.001 |
B | 150 (35.6) | 67 (38.1) | 259 (35.0) | |
C | 55 (13.1) | 29 (16.5) | 235 (31.8) | |
D | 5 (1.2) | 9 (5.1) | 147 (19.9) | |
Tumor number | ||||
≤3 | 349 (82.9) | 143 (81.7) | 619 (82.8) | 0.715 |
> 3 | 72 (17.1) | 32 (18.2) | 120 (16.2) | |
Tumor size (cm) | ||||
< 3 | 179 (42.5) | 68 (38.6) | 304 (41.1) | < 0.001 |
3–5 | 129 (30.6) | 51 (29.0) | 163 (22.1) | |
≥5 | 113 (26.8) | 57 (32.4) | 272 (36.8) | |
Hemoglobin (g/dL) | 13.0 (11.8–14.3) | 13.2 (11.3–14.5) | 13.8 (12.7–14.8) | < 0.001 |
WBC (×103/μL) | 5.1 (3.9–6.3) | 5.1 (3.9–6.3) | 5.1 (4.0–6.6) | 0.430 |
Platelet (× 103/μL) | 120 (81–165) | 132 (91–179) | 129 (87–175) | 0.406 |
Prothrombin time (INR) | 1.1 (1.0–1.2) | 1.1 (1.1–1.2) | 1.1 (1.1–1.2) | < 0.001 |
Creatinine (mg/dL) | 0.8 (0.7–1.0) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | < 0.001 |
Sodium (mEq/L) | 141 (139–142) | 139 (137–141) | 140 (138–142) | < 0.001 |
AST (mg/dL) | 42 (29–64) | 44 (33–63.5) | 49 (34–72) | 0.089 |
ALT (mg/dL) | 34 (22–54) | 33 (23–53.5) | 38 (24–58) | 0.322 |
Total bilirubin (mg/dL) | 0.8 (0.6–1.2) | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.487 |
Albumin (g/dl) | 3.8 (3.4–4.1) | 3.7 (3.4–4.0) | 3.9 (3.5–4.2) | 0.233 |
Alpha-fetoprotein (ng/mL) | ||||
≥200 | 89 (21.1) | 49 (28.5) | 194 (26.3) | 0.084 |
< 200 | 332 (78.9) | 123 (71.5) | 545 (73.4) | |
NLR | 1.85 (1.3–2.6) | 1.90 (1.3–3.1) | 1.6 (1.2–2.2) | < 0.001 |
No. of TACE sessions | 2 (1–2) | 2 (1–4) | 4 (2–7) | < 0.001 |
Tumor response | ||||
CR + PR | 332 (78.9%) | 57 (32.4%) | 616 (83.4) | < 0.001 |
SD + PD | 89 (21.1%) | 119 (67.6%) | 123 (16.6) |
Variables | Total (n = 597) | Derivation (n = 419) | Internal validation (n = 178) | P |
---|---|---|---|---|
Sex | ||||
Male | 474 (79.4) | 336 (80.2) | 138 (77.5) | 0.462 |
Female | 123 (20.6) | 83 (19.8) | 40 (22.5) | |
Age (year) | 63.9 ± 11.7 | 63.9 ± 11.8 | 64.1 ± 11.6 | 0.910 |
Etiology | ||||
HBV | 386 (64.7) | 329 (78.6) | 113 (71.1) | 0.868 |
HCV | 82 (13.7) | 62 (14.9) | 26 (16.4) | |
alcohol | 60 (10.1) | 28 (6.5) | 20 (12.5) | |
Cirrhosis | ||||
Yes | 470 (78.7%) | 336 (79.8%) | 134 (76.1%) | 0.317 |
Child-Pugh classa | ||||
A | 479 (80.2) | 340 (81.1) | 139 (78.1) | 0.391 |
B | 118 (19.8) | 79 (18.9) | 39 (21.9) | |
BCLC stage | ||||
A | 237 (39.7) | 159 (37.9) | 78 (43.8) | 0.180 |
B | 360 (60.3) | 260 (62.1) | 100 (56.2) | |
ALBI grade | ||||
1 | 204 (34.2) | 146 (34.8) | 58 (32.6) | 0.046 |
2 | 363 (60.8) | 258 (61.6) | 105 (59.0) | |
3 | 30 (5.03) | 15 (3.6) | 15 (8.4) | |
HAP score | ||||
0 | 4 (0.7) | 3 (0.7) | 1 (0.6) | 0.776 |
A | 211 (35.3) | 144 (34.4) | 67 (37.6) | |
B | 181 (30.3) | 132 (31.5) | 49 (27.5) | |
C | 154 (25.8) | 105 (25.1) | 49 (27.5) | |
D | 47 (7.9) | 35 (8.4) | 12 (6.7) | |
Modified HAP score | ||||
0 | 4 (0.7) | 3 (0.7) | 1 (0.6) | 0.847 |
A | 278 (46.6) | 189 (45.1) | 89 (50.0) | |
B | 217 (36.3) | 155 (37.0) | 62 (34.8) | |
C | 84 (14.1) | 62 (14.8) | 22 (12.4) | |
D | 14 (2.3) | 10 (2.4) | 4 (2.2) | |
Tumor number | ||||
≤3 | 492 (82.6) | 343 (82.1) | 149 (83.7) | 0.713 |
> 3 | 104 (17.4) | 75 (17.9) | 29 (16.3) | |
Tumor size (cm) | ||||
< 3 | 247 (41.4) | 169 (40.3) | 78 (43.8) | 0.725 |
3–4 | 180 (30.1) | 128 (30.5) | 52 (29.2) | |
≥5 | 170 (28.5) | 122 (29.1) | 48 (27.0) | |
Hemoglobin (g/dL) | 12.9 ± 2.1 | 13.0 ± 2.0 | 12.6 ± 2.2 | 0.08 |
WBC (×103/μL) | 5.10 (3.9–6.3) | 5.18 (3.9–6.4) | 5.01 (3.8–6.1) | 0.362 |
Platelet (×103/μL) | 128 (83–170) | 131 (84–176) | 115.5 (79–160) | 0.038 |
Prothrombin time (INR) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 0.133 |
Creatinine (mg/dL) | 0.9 (0.7–1.0) | 0.9 (0.8–1.0) | 0.9 (0.7–1.0) | 0.099 |
Sodium (mEq/L) | 138.9 ± 3.1 | 139.0 ± 3.2 | 138.7 ± 3.0 | 0.377 |
AST (mg/dL) | 42 (30–64) | 42 (30–65) | 42 (30–60) | 0.627 |
ALT (mg/dL) | 33 (22–54) | 34 (23–55) | 31 (21–54) | 0.255 |
Total bilirubin (mg/dL) | 0.8 (0.6–1.2) | 0.8 (0.6–1.1) | 0.8 (0.6–1.2) | 0.383 |
Albumin (g/dl) | 3.8 (3.4–4.1) | 3.8 (3.4–4.0) | 3.7(3.4–4.1) | 0.158 |
Alpha-fetoprotein (ng/mL) | ||||
≥200 | 138 (23.3) | 103 (24.8) | 35 (19.8) | 0.189 |
< 200 | 455 (76.7) | 313 (75.2) | 142 (80.2) | |
NLR | 1.87 (1.3–2.7) | 1.85 (1.3–2.6) | 1.95 (1.3–2.8) | 0.412 |
No. of TACE sessions | 2.9 ± 2.8 | 3.0 ± 2.8 | 2.9 ± 2.9 | 0.290 |
Tumor response | ||||
CR + PR | 389 (65.2%) | 273 (65.2%) | 116 (65.2%) | 0.997 |
SD + PD | 208 (34.8%) | 146 (34.8%) | 62 (34.8%) |
Identification of prognostic factors of OS after initial TACE treatment
Variables | Univariate analysis | Regression coefficient (ß) | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||||
Sex | |||||||
Female | 0.940 | (0.662–1.335) | 0.731 | ||||
Age (year) | 1.024 | (1.012–1.037) | < 0.001 | ||||
Etiology | |||||||
Non-Viral | ref | ||||||
Viral | 0.616 | (0.437–0.870) | 0.006 | ||||
Child-Pugh class | |||||||
A | ref | ||||||
B | 1.591 | (1.143–2.213) | 0.006 | ||||
ALBI grade | |||||||
1 | ref | ||||||
2 | 2.231 | (1.605–3.101) | <.0001 | ||||
3 | 6.602 | (3.409–12.786) | <.0001 | 0.832 | 2.299 | (1.694–3.119) | <.0001 |
HAP score | |||||||
A-C | ref | ||||||
D | 3.937 | (2.872–5.399) | <.0001 | ||||
Modified HAP score | |||||||
A-C | ref | ||||||
D | 4.689 | (3.012–7.300) | <.0001 | ||||
Tumor number | |||||||
≤3 | ref | ||||||
> 3 | 1.615 | (1.155–2.259) | 0.005 | ||||
Tumor size (cm) | |||||||
< 3 | ref | ||||||
3–4 | 1.775 | (1.231–2.560) | 0.002 | ||||
≥5 | 3.359 | (2.368–4.763) | <.0001 | 0.533 | 1.704 | (1.424–2.038) | <.0001 |
Hemoglobin (g/dL) | 0.851 | (0.796–0.909) | <.0001 | ||||
Log WBC | 1.452 | (0.988–2.132) | 0.058 | ||||
Log platelet | 1.165 | (0.875–1.551) | 0.296 | ||||
Log prothrombin time (INR) | 9.847 | (3.454–28.076) | <.0001 | ||||
Log creatinine | 1.907 | (1.377–2.640) | <.0001 | ||||
Sodium | 0.937 | (0.898–0.977) | 0.002 | ||||
Log AST | 2.332 | (1.833–2.966) | <.0001 | ||||
Log ALT | 1.231 | (1.010–1.499) | 0.039 | ||||
Log Total bilirubin | 1.191 | (0.900–1.574) | 0.221 | ||||
Alpha-fetoprotein | |||||||
< 200 | ref | ||||||
≥200 | 1.774 | (1.313–2.397) | <.0001 | 0.460 | 1.583 | (1.164–2.154) | 0.0034 |
NLR | 1.91 | (1.444–2.525) | <.0001 | ||||
Tumor response | |||||||
CR + PR | ref | ||||||
SD + PD | 2.292 | (1.733–3.032) | <.0001 | 0.650 | 1.915 | (1.431–2.563) | <.0001 |
Prediction model development for evaluating TACE suitability
Score | |||
---|---|---|---|
0 | 1 | 2 | |
ALBI grade | 1 | 2 | 3 |
Maximal tumor diameter (cm) | < 3 | 3–5 | ≥5 |
AFP (ng/mL) | < 200 | ≥200 | |
Tumor response | CR, PR | SD, PD |